pharma · hidradenitis suppurativa (HS) · Hidradenitis Suppurativa · MLTX
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (NASDAQ: is a pharma organization headquartered in Zug, CH. It trades on NYSE under ticker MLTX. Primary therapeutic focus areas include hidradenitis suppurativa (HS), Hidradenitis Suppurativa
Dorfstrasse, 29, Zug 6300, CH HQ
2021 Founded
133 Employees
Public company Type
MLTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Dorfstrasse, 29, Zug 6300, CH
- Founded
- 2021
- Employees
- 133
- Programs
- 13
- Drugs
- 11
- Patents
- 0
Sonelokimab (M1095)
Phase 2 · small molecule · Hidradenitis Suppurativa
Sonelokimab (M1095) for Hidradenitis Suppurativa is a Phase 2 program (small_molecule) at MoonLake Immunotherapeutics with 1 ClinicalTrials.gov record(s).
Internal code M1095-HS-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- MoonLake Immunotherapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Hidradenitis Suppurativa
- Status
- completed
- Trials
- 1